AZD8055: Technical Guidance for Research Applications

What This Product Solves

AZD8055 (SKU A8214) is a potent, selective ATP-competitive mTOR inhibitor designed for use in mechanistic studies involving the mTOR signaling pathway. As a dual mTORC1/mTORC2 inhibitor, AZD8055 enables researchers to dissect the roles of these complexes in cancer biology and metabolic regulation. Its high selectivity (approximately 1000-fold over PI3K isoforms and ATM/DNA-PK) and strong activity at nanomolar concentrations support detailed pathway analysis without significant off-target kinase effects. AZD8055 is not recommended for studies that require demonstration of clinical efficacy, due to minimal results in late-phase clinical trials (product information).

Internal technical articles, such as AZD8055: Practical Use of a Selective mTOR Inhibitor in Research, reinforce that this compound is optimal for robust preclinical pathway interrogation but not for translational efficacy endpoints.

Protocol Parameters

• Solubility for Stock Solutions: ≥23.3 mg/mL in DMSO | Suitable for preparing high-concentration stocks for in vitro and in vivo studies | Ensures accurate dosing and compound stability | Product dossier
• Recommended Storage: -20°C (solid form) | Maintains compound integrity over time | Prevents degradation and preserves inhibitory potency | Product dossier
• Working Solution Handling: Use solutions promptly; do not store long-term | Minimizes risk of hydrolysis and potency loss in DMSO | Supports reproducible experimental results | Product dossier
• Assay Concentration Range: Nanomolar scale (workflow rec.: 1–100 nM for cell assays) | Enables targeted inhibition of mTORC1/mTORC2 in cell-based systems | Reflects observed efficacy in multiple preclinical cancer cell lines | Workflow recommendation
• Vehicle Compatibility: Insoluble in water and ethanol; use DMSO | Ensures complete solubilization for biological assays | Avoids precipitation and dosing inconsistencies | Product dossier
• Animal Model Administration: Intraperitoneal injection (workflow rec.) | Supports systemic exposure for in vivo pathway studies | Based on preclinical usage patterns | Workflow recommendation

Workflow Setup and QC Checklist

• Stock Preparation: Dissolve AZD8055 in 100% DMSO at a concentration no greater than 23.3 mg/mL. Vortex and inspect visually to ensure complete dissolution before dilution.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze-thaw cycles, which can degrade the compound.
• Working Solution: Dilute stocks into culture medium immediately before use. Final DMSO concentrations in assays should not exceed 0.1–0.2% to minimize cellular toxicity.
• Negative Controls: Include equivalent DMSO vehicle controls in all experimental arms to distinguish compound effect from solvent effects.
• Verification: Confirm compound identity and purity upon receipt by LC-MS or NMR, if available, for critical studies.
• Documentation: Record lot number, preparation date, and storage history for each batch used.

Common Failure Modes and Fixes

• Precipitation in Aqueous Media: AZD8055 is insoluble in water and ethanol. If precipitate forms after dilution, check that DMSO concentration in the final solution is adequate. Redissolve in DMSO and add to media slowly with vortexing.
• Loss of Activity: Using aged or repeatedly thawed solutions can reduce inhibitor potency. Always use freshly thawed, single-use aliquots and avoid long-term storage of diluted solutions.
• Inconsistent Cellular Response: High DMSO levels can affect cell viability. Ensure DMSO does not exceed recommended levels in the final assay. Verify compound integrity if unexpected results occur.
• Vehicle Effects Misinterpreted as Compound Activity: Always run matched DMSO controls to distinguish true mTOR pathway inhibition from nonspecific effects.

Scope and Limitations

AZD8055 is optimized for preclinical research requiring selective inhibition of both mTORC1 and mTORC2. It is particularly suited to studies interrogating the PI3K/Akt/mTOR signaling cascade in cancer and metabolic models, and can be used to assess changes in proliferation markers such as Ki67 in vitro. The compound has also demonstrated modulation of glucose metabolism and insulin levels in animal models. However, it is not suitable for studies aiming to demonstrate clinical efficacy or translational benefit, as phase I clinical trials revealed minimal impact at the patient level (product information).

For additional best-practice recommendations, the article Technical Guidance for Using AZD8055 as an mTOR Inhibitor provides troubleshooting and workflow setup advice, complementing the present guide.

Conclusion

AZD8055 is a rigorously characterized tool compound for mechanistic dissection of mTOR signaling, offering robust selectivity and potency in preclinical models. Careful attention to solubilization, storage, and vehicle controls is essential for reproducible results. Researchers should use AZD8055 for pathway analysis in cancer and metabolic studies and avoid its application in projects where clinical efficacy is the primary endpoint. For further details, refer to the AZD8055 product page at APExBIO.